#CBCII transcript

Healthcare Social Media Transcript

From: Fri Sep 09 0:00:00 PDT 2016
To: Tue Sep 13 0:00:00 PDT 2016

What is #CBCII? Who were the influencers during this time period? #CBCII analytics


Healthcare Conference  - Healthcare Tweet Chats  -  Healthcare Analytics

prof_labeyonce
https://pbs.twimg.com/profile_images/604101052569382913/_yteC_1R_normal.jpg
RT @evemariecrane: First US olympic gold medalist in figure skating-1956, also studied #biomarkers wow #STEMWomen Inspiring for #CBCII! https://t.co/wcanHtl4ef
gizbab
https://pbs.twimg.com/profile_images/3496192357/5f6dcb29a6ac0eafeb21ff708f320bf3_normal.jpeg
RT @evemariecrane: First US olympic gold medalist in figure skating-1956, also studied #biomarkers wow #STEMWomen Inspiring for #CBCII! https://t.co/wcanHtl4ef
karla_crane
https://pbs.twimg.com/profile_images/378800000156872972/daddead3013769b3a098bd7803ff4b07_normal.jpeg
RT @evemariecrane: First US olympic gold medalist in figure skating-1956, also studied #biomarkers wow #STEMWomen Inspiring for #CBCII! https://t.co/wcanHtl4ef
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Cancer biomarkers conference: tomorrow! Follow #CBCII for updates 🗣🔬📲 #pathology #cancer https://t.co/Z66v37184t https://t.co/xHh1xfzzDF
evemariecrane
https://pbs.twimg.com/profile_images/763589336621133829/hp9TxZSp_normal.jpg
RT @marenwhymd: Cancer biomarkers conference: tomorrow! Follow #CBCII for updates 🗣🔬📲 #pathology #cancer https://t.co/Z66v37184t https://t.co/xHh1xfzzDF
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
RT @marenwhymd: Cancer biomarkers conference: tomorrow! Follow #CBCII for updates 🗣🔬📲 #pathology #cancer https://t.co/Z66v37184t https://t.co/xHh1xfzzDF
jmgardnermd
https://pbs.twimg.com/profile_images/650723237148643328/LypaAN2q_normal.jpg
#Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
khalid_alharari
https://pbs.twimg.com/profile_images/747830861647716353/MLeBK12A_normal.jpg
RT @JMGardnerMD: #Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
pathologists
https://pbs.twimg.com/profile_images/555843459756478464/-3O9nqf-_normal.png
RT @JMGardnerMD: #Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
sara_jiang
https://pbs.twimg.com/profile_images/743117496023195648/Wj_hDxYt_normal.jpg
RT @JMGardnerMD: #Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
sara_jiang
https://pbs.twimg.com/profile_images/743117496023195648/Wj_hDxYt_normal.jpg
RT @marenwhymd: Cancer biomarkers conference: tomorrow! Follow #CBCII for updates 🗣🔬📲 #pathology #cancer https://t.co/Z66v37184t https://t.co/xHh1xfzzDF
jimchap
https://pbs.twimg.com/profile_images/716741000698458112/usong8kD_normal.jpg
RT @JMGardnerMD: #Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
carnold_gi
https://pbs.twimg.com/profile_images/664520482520076288/8lW_MVDD_normal.jpg
RT @JMGardnerMD: #Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
nglmr1000
https://pbs.twimg.com/profile_images/614408117657411584/dCjod8zs_normal.jpg
RT @JMGardnerMD: #Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @JMGardnerMD: #Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
david_hzt
https://pbs.twimg.com/profile_images/631548674615566337/s368O_gz_normal.jpg
RT @evemariecrane: First US olympic gold medalist in figure skating-1956, also studied #biomarkers wow #STEMWomen Inspiring for #CBCII! https://t.co/wcanHtl4ef
smlungpathguy
https://pbs.twimg.com/profile_images/780941743004880896/M03kC6kx_normal.jpg
RT @JMGardnerMD: #Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
mreyesm
https://pbs.twimg.com/profile_images/672100995749437441/miGZvrjw_normal.jpg
RT @JMGardnerMD: #Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
jmgardnermd
https://pbs.twimg.com/profile_images/650723237148643328/LypaAN2q_normal.jpg
RT @marenwhymd: Cancer biomarkers conference: tomorrow! Follow #CBCII for updates 🗣🔬📲 #pathology #cancer https://t.co/Z66v37184t https://t.co/xHh1xfzzDF
jmgardnermd
https://pbs.twimg.com/profile_images/650723237148643328/LypaAN2q_normal.jpg
RT @evemariecrane: First US olympic gold medalist in figure skating-1956, also studied #biomarkers wow #STEMWomen Inspiring for #CBCII! https://t.co/wcanHtl4ef
katepens
https://pbs.twimg.com/profile_images/772930718351720448/QI7Zuj6M_normal.jpg
RT @evemariecrane: First US olympic gold medalist in figure skating-1956, also studied #biomarkers wow #STEMWomen Inspiring for #CBCII! https://t.co/wcanHtl4ef
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Follow #CBCII for Cancer Biomarkers Conference II this weekend. #pathologists
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Follow #CBCII for Cancer Biomarkers Conference II this weekend. #pathologists
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
RT @euthman: Follow #CBCII for Cancer Biomarkers Conference II this weekend. #pathologists
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
At the beautiful @MethodistHosp for #CBCII today. Great program ahead. https://t.co/rIPVlEOBcN
healthhashtags
https://pbs.twimg.com/profile_images/776176153593720832/e_wO9ivm_normal.jpg
Today's Healthcare Conferences: #wais #dgfn2016 #wais2016 #CIRSE2016 #CBCII https://t.co/YnZewsLKhm #hcsm
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Venue for #CBCII https://t.co/yBjoQo24Nz
robyn_temple
https://pbs.twimg.com/profile_images/631506130892640256/VgHCIwHF_normal.jpg
Hope you have a great #CBCII @PhilipTCagle!
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Charged up and ready to go! ☕️📲 #CBCII https://t.co/epYpo0qiLq
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @euthman: Follow #CBCII for Cancer Biomarkers Conference II this weekend. #pathologists
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Cancer Biomarkers Conference II is a sellout! But #pathologists can follow the proceedings via live-tweeters tagging posts as #CBCII
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
.@PhilipTCagle Introduces the attendees- 23 states, multiple countries shoutout to @Nathan_E_Lee #CBCII https://t.co/tFDY9DTShu
sara_jiang
https://pbs.twimg.com/profile_images/743117496023195648/Wj_hDxYt_normal.jpg
RT @euthman: Cancer Biomarkers Conference II is a sellout! But #pathologists can follow the proceedings via live-tweeters tagging posts as #CBCII
drsybenga
https://pbs.twimg.com/profile_images/595981337196163072/OxROyC10_normal.jpg
RT @TimAllenMDJD: At the beautiful @MethodistHosp for #CBCII today. Great program ahead. https://t.co/rIPVlEOBcN
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
First up, keynote by Daniel F. Hayes, ASC prez, on future of Biomarkers. #CBCII
sara_jiang
https://pbs.twimg.com/profile_images/743117496023195648/Wj_hDxYt_normal.jpg
RT @marenwhymd: .@PhilipTCagle Introduces the attendees- 23 states, multiple countries shoutout to @Nathan_E_Lee #CBCII https://t.co/tFDY9DTShu
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
First speaker: @asco President Daniel Hayes #CBCII https://t.co/nOo6pUiMZ9
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @euthman: Cancer Biomarkers Conference II is a sellout! But #pathologists can follow the proceedings via live-tweeters tagging posts as #CBCII
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Medical-industrial complex? You bet! #CBCII https://t.co/q7DCtScRON
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Why and when use Biomarkers? #CBCII https://t.co/sdReMewllA
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
"Think like a scientist and think like a clinician" -Dr Hayes on relevant medical research #science #medicine #CBCII https://t.co/5W98cjLUYe
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
Happy to be at the Cancer Biomarkers Conf at Methodist! #CBCII #pathologist #cancer https://t.co/xJwAPlquA7
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
RT @marenwhymd: "Think like a scientist and think like a clinician" -Dr Hayes on relevant medical research #science #medicine #CBCII https://t.co/5W98cjLUYe
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Tumor biomarkers go back to estrogen receptors in 1971. #CBCII
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @YasmeenButtMD: Happy to be at the Cancer Biomarkers Conf at Methodist! #CBCII #pathologist #cancer https://t.co/xJwAPlquA7
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
RT @YasmeenButtMD: Happy to be at the Cancer Biomarkers Conf at Methodist! #CBCII #pathologist #cancer https://t.co/xJwAPlquA7
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
@DrSybenga hashtag #CBCII 😁
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
#CBCII https://t.co/ClfgP5JRgW
imedicalbilling
https://pbs.twimg.com/profile_images/766371685524082688/YjLC588z_normal.jpg
RT @marenwhymd: "Think like a scientist and think like a clinician" -Dr Hayes on relevant medical research #science #medicine #CBCII https://t.co/5W98cjLUYe
becadodeselebro
https://pbs.twimg.com/profile_images/781185987133206528/ViY_F3cO_normal.jpg
RT @marenwhymd: "Think like a scientist and think like a clinician" -Dr Hayes on relevant medical research #science #medicine #CBCII https://t.co/5W98cjLUYe
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Precision medicine already well established. #CBCII https://t.co/wAmImIUOBR
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
#CBCII is underway! #StandingRoomOnly https://t.co/hciMgLF5US
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
RT @euthman: First up, keynote by Daniel F. Hayes, ASC prez, on future of Biomarkers. #CBCII
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
RT @marenwhymd: .@PhilipTCagle Introduces the attendees- 23 states, multiple countries shoutout to @Nathan_E_Lee #CBCII https://t.co/tFDY9DTShu
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
ALL doctors provide personalized medicine -Dr Hayes #CBCII #personalizedmedicine https://t.co/DyRxXwqAzS
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
RT @euthman: Why and when use Biomarkers? #CBCII https://t.co/sdReMewllA
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
#CBCII https://t.co/IICsR2KgEA
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @TimAllenMDJD: #CBCII is underway! #StandingRoomOnly https://t.co/hciMgLF5US
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
#CBCII https://t.co/5JHO1oC3qj
drsybenga
https://pbs.twimg.com/profile_images/595981337196163072/OxROyC10_normal.jpg
@MethodistHosp Excited to hear @TimAllenMDJD & @PhilipTCagle speak #CBCII conference! @Pathologists @marenwhymd https://t.co/zxqca6VW4A
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Test vs. Biomarker. #CBCII https://t.co/4abBGmAAvx
pathology20
https://pbs.twimg.com/profile_images/561663935980793856/0fM_co_B_normal.jpeg
Dr. Dan Hayes, ASCO Pres, kicks off Cancer Biomarkers "Perspectives on the Future of Cancer Biomarkers". #CBCII https://t.co/UQGxe8H2ig
tissuepathology
https://pbs.twimg.com/profile_images/561663819614019584/IIbVbRHC_normal.jpeg
Dr. Dan Hayes, ASCO Pres, kicks off Cancer Biomarkers "Perspectives on the Future of Cancer Biomarkers". #CBCII https://t.co/GK9iiQ2bPq
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @euthman: Test vs. Biomarker. #CBCII https://t.co/4abBGmAAvx
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Why @ASCO recommendations are so conservative. #CBCII https://t.co/21PK0hmz7G
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @euthman: Why @ASCO recommendations are so conservative. #CBCII https://t.co/21PK0hmz7G
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
When is a biomarker clinically useful? #CBCII https://t.co/MzLmcT4Xk6
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @tissuepathology: Dr. Dan Hayes, ASCO Pres, kicks off Cancer Biomarkers "Perspectives on the Future of Cancer Biomarkers". #CBCII https://t.co/GK9iiQ2bPq
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @DrSybenga: @MethodistHosp Excited to hear @TimAllenMDJD & @PhilipTCagle speak #CBCII conference! @Pathologists @marenwhymd https://t.co/zxqca6VW4A
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @TimAllenMDJD: #CBCII is underway! #StandingRoomOnly https://t.co/hciMgLF5US
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @YasmeenButtMD: Happy to be at the Cancer Biomarkers Conf at Methodist! #CBCII #pathologist #cancer https://t.co/xJwAPlquA7
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @YasmeenButtMD: Happy to be at the Cancer Biomarkers Conf at Methodist! #CBCII #pathologist #cancer https://t.co/xJwAPlquA7
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @marenwhymd: "Think like a scientist and think like a clinician" -Dr Hayes on relevant medical research #science #medicine #CBCII https://t.co/5W98cjLUYe
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @euthman: First up, keynote by Daniel F. Hayes, ASC prez, on future of Biomarkers. #CBCII
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @marenwhymd: .@PhilipTCagle Introduces the attendees- 23 states, multiple countries shoutout to @Nathan_E_Lee #CBCII https://t.co/tFDY9DTShu
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @euthman: Cancer Biomarkers Conference II is a sellout! But #pathologists can follow the proceedings via live-tweeters tagging posts as #CBCII
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @marenwhymd: Charged up and ready to go! ☕️📲 #CBCII https://t.co/epYpo0qiLq
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @Robyn_Temple: Hope you have a great #CBCII @PhilipTCagle!
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @TimAllenMDJD: At the beautiful @MethodistHosp for #CBCII today. Great program ahead. https://t.co/rIPVlEOBcN
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @euthman: Follow #CBCII for Cancer Biomarkers Conference II this weekend. #pathologists
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @JMGardnerMD: #Pathologists involvement in Facebook patient groups. Watch my lecture live via periscope tmrw 9/10 @ 1pm CST #CBCII https://t.co/0PFC4oozQh
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Difference between FDA-approved and lab-developed tests. Clinical utility NOT required for either. #CBCII https://t.co/gEcSpfhLdr
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Semantics of biomarker testing. #CBCII https://t.co/HAlFzg60bB
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Venue for #CBCII https://t.co/yBjoQo24Nz
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Cancer Biomarkers Conference II is a sellout! But #pathologists can follow the proceedings via live-tweeters tagging posts as #CBCII
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: First up, keynote by Daniel F. Hayes, ASC prez, on future of Biomarkers. #CBCII
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Medical-industrial complex? You bet! #CBCII https://t.co/q7DCtScRON
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Semantics are impt. Pay attention to Clinical utility -Dr Hayes #CBCII https://t.co/8DpzK9wOZK
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Why and when use Biomarkers? #CBCII https://t.co/sdReMewllA
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Tumor biomarkers go back to estrogen receptors in 1971. #CBCII
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @euthman: Difference between FDA-approved and lab-developed tests. Clinical utility NOT required for either. #CBCII https://t.co/gEcSpfhLdr
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Precision medicine already well established. #CBCII https://t.co/wAmImIUOBR
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Test vs. Biomarker. #CBCII https://t.co/4abBGmAAvx
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Why @ASCO recommendations are so conservative. #CBCII https://t.co/21PK0hmz7G
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Vicious cycle that undervalues tumor biomarkers. #CBCII https://t.co/gSCnJDLNis
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: When is a biomarker clinically useful? #CBCII https://t.co/MzLmcT4Xk6
pirumgi
https://pbs.twimg.com/profile_images/582195802421882880/0TajLMk8_normal.jpg
RT @marenwhymd: Semantics are impt. Pay attention to Clinical utility -Dr Hayes #CBCII https://t.co/8DpzK9wOZK
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Difference between FDA-approved and lab-developed tests. Clinical utility NOT required for either. #CBCII https://t.co/gEcSpfhLdr
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
RT @euthman: Difference between FDA-approved and lab-developed tests. Clinical utility NOT required for either. #CBCII https://t.co/gEcSpfhLdr
jmgardnermd
https://pbs.twimg.com/profile_images/650723237148643328/LypaAN2q_normal.jpg
RT @euthman: Follow #CBCII for Cancer Biomarkers Conference II this weekend. #pathologists
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
The muck of chaos - creating a good test. #CBCII #pathologists https://t.co/Hln0amdFqE
jmgardnermd
https://pbs.twimg.com/profile_images/650723237148643328/LypaAN2q_normal.jpg
RT @euthman: Vicious cycle that undervalues tumor biomarkers. #CBCII https://t.co/gSCnJDLNis
jmgardnermd
https://pbs.twimg.com/profile_images/650723237148643328/LypaAN2q_normal.jpg
RT @euthman: Difference between FDA-approved and lab-developed tests. Clinical utility NOT required for either. #CBCII https://t.co/gEcSpfhLdr
jmgardnermd
https://pbs.twimg.com/profile_images/650723237148643328/LypaAN2q_normal.jpg
RT @euthman: When is a biomarker clinically useful? #CBCII https://t.co/MzLmcT4Xk6
jmgardnermd
https://pbs.twimg.com/profile_images/650723237148643328/LypaAN2q_normal.jpg
RT @euthman: Cancer Biomarkers Conference II is a sellout! But #pathologists can follow the proceedings via live-tweeters tagging posts as #CBCII
sesiegler
https://pbs.twimg.com/profile_images/792863545025257472/oxe9Ztnw_normal.jpg
RT @euthman: Vicious cycle that undervalues tumor biomarkers. #CBCII https://t.co/gSCnJDLNis
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @YasmeenButtMD: The muck of chaos - creating a good test. #CBCII #pathologists https://t.co/Hln0amdFqE
sesiegler
https://pbs.twimg.com/profile_images/792863545025257472/oxe9Ztnw_normal.jpg
RT @euthman: Semantics of biomarker testing. #CBCII https://t.co/HAlFzg60bB
quiqueparada
https://pbs.twimg.com/profile_images/758006466594738176/mjXzT-c5_normal.jpg
RT @marenwhymd: ALL doctors provide personalized medicine -Dr Hayes #CBCII #personalizedmedicine https://t.co/DyRxXwqAzS
sesiegler
https://pbs.twimg.com/profile_images/792863545025257472/oxe9Ztnw_normal.jpg
RT @euthman: Follow #CBCII for Cancer Biomarkers Conference II this weekend. #pathologists
raghupillappa
https://pbs.twimg.com/profile_images/709068109252964352/NEK0XKmt_normal.jpg
RT @PhilipTCagle: #CBCII https://t.co/RPOrEwJdSy sponsored #HMPath @Pathologists & @PulmPathSoc @_SaranyaS_ @raghupillappa @YasmeenButtMD @Sinchita_Roy
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Liquid biopsies. #CBCII https://t.co/O57gStTART
jmgardnermd
https://pbs.twimg.com/profile_images/650723237148643328/LypaAN2q_normal.jpg
RT @tissuepathology: Dr. Dan Hayes, ASCO Pres, kicks off Cancer Biomarkers "Perspectives on the Future of Cancer Biomarkers". #CBCII https://t.co/GK9iiQ2bPq
jmgardnermd
https://pbs.twimg.com/profile_images/650723237148643328/LypaAN2q_normal.jpg
RT @marenwhymd: "Think like a scientist and think like a clinician" -Dr Hayes on relevant medical research #science #medicine #CBCII https://t.co/5W98cjLUYe
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Circulating KRAS assay FDA-approved in June, 2016. #CBCII https://t.co/6G3HXKxTyn
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
Approved circulating KRAS assay. #CBCII #pathologists
tissuepathology
https://pbs.twimg.com/profile_images/561663819614019584/IIbVbRHC_normal.jpeg
Dr. Dan Hayes, ASCO President on Circulating "Liquid" vs. Tissue Biopsy #CBCII https://t.co/RRvuHxdChB
pathology20
https://pbs.twimg.com/profile_images/561663935980793856/0fM_co_B_normal.jpeg
Dr. Dan Hayes, ASCO President on Circulating "Liquid" vs. Tissue Biopsy #CBCII https://t.co/KrEuszPV1T
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
RT @DrSybenga: @MethodistHosp Excited to hear @TimAllenMDJD & @PhilipTCagle speak #CBCII conference! @Pathologists @marenwhymd https://t.co/zxqca6VW4A
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
RT @TimAllenMDJD: #CBCII is underway! #StandingRoomOnly https://t.co/hciMgLF5US
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Future of tumor biomarkers. "Our patients deserve better" -Dr Hayes #CBCII #cancer #CancerMoonshot https://t.co/u9uN6swNpM
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Semantics of biomarker testing. #CBCII https://t.co/HAlFzg60bB
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Vicious cycle that undervalues tumor biomarkers. #CBCII https://t.co/gSCnJDLNis
sesiegler
https://pbs.twimg.com/profile_images/792863545025257472/oxe9Ztnw_normal.jpg
RT @tissuepathology: Dr. Dan Hayes, ASCO President on Circulating "Liquid" vs. Tissue Biopsy #CBCII https://t.co/RRvuHxdChB
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Liquid biopsies. #CBCII https://t.co/O57gStTART
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Circulating KRAS assay FDA-approved in June, 2016. #CBCII https://t.co/6G3HXKxTyn
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Next up, rationale of pt. selection and Rx based on biomarkers, by Eric Bernicker. #CBCII
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Next, Dr Eric Bernicker on how biomarkers influence patient care #CBCII #cancer #oncology https://t.co/78aiMiHWu8
pirumgi
https://pbs.twimg.com/profile_images/582195802421882880/0TajLMk8_normal.jpg
RT @euthman: Difference between FDA-approved and lab-developed tests. Clinical utility NOT required for either. #CBCII https://t.co/gEcSpfhLdr
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
"Constantly choosing the lesser of two evils is still evil."—Jerry Garcia. #CBCII https://t.co/qIpfHo5qUw
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
What FDA says and what clinicians hear. #CBCII #pathologists https://t.co/sAq3PCNF4I
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @euthman: "Constantly choosing the lesser of two evils is still evil."—Jerry Garcia. #CBCII https://t.co/qIpfHo5qUw
amyhdeekenmd
https://pbs.twimg.com/profile_images/378800000656361090/78c4f4e5dc57295cc185c47690486bba_normal.jpeg
RT @marenwhymd: Future of tumor biomarkers. "Our patients deserve better" -Dr Hayes #CBCII #cancer #CancerMoonshot https://t.co/u9uN6swNpM
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @YasmeenButtMD: What FDA says and what clinicians hear. #CBCII #pathologists https://t.co/sAq3PCNF4I
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
EGFR testing in non-small cell lung cancer. #CBCII https://t.co/Eo2uUOMqMy
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
Promise of personalized therapy in lung cancer. #CBCII #pathologists #pulmpath https://t.co/TpLyZzm8PH
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
RT @euthman: "Constantly choosing the lesser of two evils is still evil."—Jerry Garcia. #CBCII https://t.co/qIpfHo5qUw
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @YasmeenButtMD: Promise of personalized therapy in lung cancer. #CBCII #pathologists #pulmpath https://t.co/TpLyZzm8PH
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Wtf is a "waterfall plot"? #CBCII
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
Targeted agents for lung cancer. NCCN Guidelines. #CBCII #pathologists #pulmpath https://t.co/Z27a37Q0bt
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Emerging targeted agents. #CBCII https://t.co/4J90YrLWrP
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
We don't start therapy until we get EGFR/ALK back -Dr Bernicker on the importance of biomarkers #lungcancer #CBCII https://t.co/n6PfFoe6GU
acsoroc
https://pbs.twimg.com/profile_images/767521451838672896/FM05mnCw_normal.jpg
RT @euthman: Circulating KRAS assay FDA-approved in June, 2016. #CBCII https://t.co/6G3HXKxTyn
acsoroc
https://pbs.twimg.com/profile_images/767521451838672896/FM05mnCw_normal.jpg
RT @euthman: Liquid biopsies. #CBCII https://t.co/O57gStTART
acsoroc
https://pbs.twimg.com/profile_images/767521451838672896/FM05mnCw_normal.jpg
RT @YasmeenButtMD: What FDA says and what clinicians hear. #CBCII #pathologists https://t.co/sAq3PCNF4I
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
@Tom_J_Giordano @tissuepathology My impression was more emphasis on clinical validation, whether it be FDA or LDT #CBCII
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Oncologists must be able to gestalt their gobbledegook statistical graphs the way #pathologists do low-power microscope views. #CBCII
acsoroc
https://pbs.twimg.com/profile_images/767521451838672896/FM05mnCw_normal.jpg
RT @tissuepathology: Dr. Dan Hayes, ASCO President on Circulating "Liquid" vs. Tissue Biopsy #CBCII https://t.co/RRvuHxdChB
tissuedetective
https://pbs.twimg.com/profile_images/702925153752068096/uQW2YpCZ_normal.jpg
RT @euthman: Liquid biopsies. #CBCII https://t.co/O57gStTART
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Next up, rationale of pt. selection and Rx based on biomarkers, by Eric Bernicker. #CBCII
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: "Constantly choosing the lesser of two evils is still evil."—Jerry Garcia. #CBCII https://t.co/qIpfHo5qUw
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: EGFR testing in non-small cell lung cancer. #CBCII https://t.co/Eo2uUOMqMy
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Emerging targeted agents. #CBCII https://t.co/4J90YrLWrP
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Oncologists must be able to gestalt their gobbledegook statistical graphs the way #pathologists do low-power microscope views. #CBCII
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Example of oncologist graphic. FYI. Not quitting my day job. #CBCII https://t.co/PUxYzbfA4g
pathology20
https://pbs.twimg.com/profile_images/561663935980793856/0fM_co_B_normal.jpeg
RT @euthman: Difference between FDA-approved and lab-developed tests. Clinical utility NOT required for either. #CBCII https://t.co/gEcSpfhLdr
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Which GE junction adenoca pts benefit from her2 testing? #CBCII https://t.co/BATkFEnM4n
tissuepathology
https://pbs.twimg.com/profile_images/561663819614019584/IIbVbRHC_normal.jpeg
RT @marenwhymd: @Tom_J_Giordano @tissuepathology My impression was more emphasis on clinical validation, whether it be FDA or LDT #CBCII
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @euthman: Which GE junction adenoca pts benefit from her2 testing? #CBCII https://t.co/BATkFEnM4n
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Dr Bernicker on recent advances in #braincancer #CBCII Even a pathologist can see the survival difference👍 @euthman https://t.co/XO1lnIDV3b
tedgroschscifi
https://pbs.twimg.com/profile_images/421038031546507264/oKaaDdGm_normal.jpeg
RT @marenwhymd: "Think like a scientist and think like a clinician" -Dr Hayes on relevant medical research #science #medicine #CBCII https://t.co/5W98cjLUYe
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Timely question from Dr Bernicker: "Is PDL1 a Biomarker?" #CBCII #PDL1 #immunotherapy https://t.co/O1m5jBVnE7
soyujwagle
https://pbs.twimg.com/profile_images/728805706309074944/r_2GGzgx_normal.jpg
RT @marenwhymd: "Think like a scientist and think like a clinician" -Dr Hayes on relevant medical research #science #medicine #CBCII https://t.co/5W98cjLUYe
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Next up at #CBCII , Sinchita Roy-Chowdhuri on preanalytical specimen handling.
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Now @Sinchita_Roy on Preanalytic Specimen Collection and Handling #CBCII https://t.co/HAMM79hU4U
bhas_dr
https://pbs.twimg.com/profile_images/778226429724987396/XxeHRyJD_normal.jpg
RT @marenwhymd: Now @Sinchita_Roy on Preanalytic Specimen Collection and Handling #CBCII https://t.co/HAMM79hU4U
williamson_sr
https://pbs.twimg.com/profile_images/711518021945315328/72SblwTS_normal.jpg
RT @YasmeenButtMD: What FDA says and what clinicians hear. #CBCII #pathologists https://t.co/sAq3PCNF4I
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
.@Sinchita_Roy on estimating tumor cellularity: "We're not very consistent" #CBCII https://t.co/T1t97Eu6cg
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
We're overestimating tumor fractions. 🤔 #CBCII #pathologists https://t.co/dci2nDBO2l
drsybenga
https://pbs.twimg.com/profile_images/595981337196163072/OxROyC10_normal.jpg
RT @YasmeenButtMD: We're overestimating tumor fractions. 🤔 #CBCII #pathologists https://t.co/dci2nDBO2l
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
Assessing tumor cellularity. @Sinchita_Roy #CBCII #pathologists https://t.co/6mTKQQeGew
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @YasmeenButtMD: Assessing tumor cellularity. @Sinchita_Roy #CBCII #pathologists https://t.co/6mTKQQeGew
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Example of oncologist graphic. FYI. Not quitting my day job. #CBCII https://t.co/PUxYzbfA4g
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Which GE junction adenoca pts benefit from her2 testing? #CBCII https://t.co/BATkFEnM4n
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Next up at #CBCII , Sinchita Roy-Chowdhuri on preanalytical specimen handling.
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @YasmeenButtMD: Assessing tumor cellularity. @Sinchita_Roy #CBCII #pathologists https://t.co/6mTKQQeGew
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Cellularity and tumor fraction and risk of test failure. #CBCII https://t.co/eTImw5lcD2
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: Dr Bernicker on recent advances in #braincancer #CBCII Even a pathologist can see the survival difference👍 @euthman https://t.co/XO1lnIDV3b
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: Timely question from Dr Bernicker: "Is PDL1 a Biomarker?" #CBCII #PDL1 #immunotherapy https://t.co/O1m5jBVnE7
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: Now @Sinchita_Roy on Preanalytic Specimen Collection and Handling #CBCII https://t.co/HAMM79hU4U
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: .@Sinchita_Roy on estimating tumor cellularity: "We're not very consistent" #CBCII https://t.co/T1t97Eu6cg
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Again, the Her2 #breastcancer story as a paradigm for biomarkers: Preanalytic variables matter! #CBCII @Sinchita_Roy https://t.co/1uxF3F4aOl
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Potential sources of preanalytical test variability. #CBCII https://t.co/QdU0C8zgi9
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @euthman: Potential sources of preanalytical test variability. #CBCII https://t.co/QdU0C8zgi9
santamariale
https://pbs.twimg.com/profile_images/2400232245/o6km2q2hrxlqvysyy2vo_normal.jpeg
RT @euthman: "Constantly choosing the lesser of two evils is still evil."—Jerry Garcia. #CBCII https://t.co/qIpfHo5qUw
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Summary of recs for preanalytic handling for FFPE #CBCII @Sinchita_Roy https://t.co/5nl9QMKwOB
bhas_dr
https://pbs.twimg.com/profile_images/778226429724987396/XxeHRyJD_normal.jpg
RT @YasmeenButtMD: Assessing tumor cellularity. @Sinchita_Roy #CBCII #pathologists https://t.co/6mTKQQeGew
bhas_dr
https://pbs.twimg.com/profile_images/778226429724987396/XxeHRyJD_normal.jpg
RT @marenwhymd: .@Sinchita_Roy on estimating tumor cellularity: "We're not very consistent" #CBCII https://t.co/T1t97Eu6cg
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Molecular testing on #cytology specimens. #cytologyrules, but don't forget validation! @Sinchita_Roy #CBCII https://t.co/DVTKnPdkdz
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Molecular testing of FNA specimens. #CBCII https://t.co/OoD5XqvDoO
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
RT @marenwhymd: Molecular testing on #cytology specimens. #cytologyrules, but don't forget validation! @Sinchita_Roy #CBCII https://t.co/DVTKnPdkdz
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @marenwhymd: .@Sinchita_Roy on estimating tumor cellularity: "We're not very consistent" #CBCII https://t.co/T1t97Eu6cg
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @marenwhymd: Now @Sinchita_Roy on Preanalytic Specimen Collection and Handling #CBCII https://t.co/HAMM79hU4U
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @YasmeenButtMD: What FDA says and what clinicians hear. #CBCII #pathologists https://t.co/sAq3PCNF4I
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @tissuepathology: Dr. Dan Hayes, ASCO President on Circulating "Liquid" vs. Tissue Biopsy #CBCII https://t.co/RRvuHxdChB
philiptcagle
https://pbs.twimg.com/profile_images/682262898312253440/zJxmTZNZ_normal.jpg
RT @euthman: Difference between FDA-approved and lab-developed tests. Clinical utility NOT required for either. #CBCII https://t.co/gEcSpfhLdr
pathology20
https://pbs.twimg.com/profile_images/561663935980793856/0fM_co_B_normal.jpeg
Advantages and Disadvantages of Molecular Testing of Cytology Specimens #CBCII @Pathologists https://t.co/2KDGnUZomG
tissuepathology
https://pbs.twimg.com/profile_images/561663819614019584/IIbVbRHC_normal.jpeg
Advantages and Disadvantages of Molecular Testing of Cytology Specimens #CBCII @Pathologists https://t.co/dpzBfMC4Kc
stanfordpath
https://pbs.twimg.com/profile_images/747923625727033344/mI29fR9m_normal.jpg
RT @YasmeenButtMD: We're overestimating tumor fractions. 🤔 #CBCII #pathologists https://t.co/dci2nDBO2l
stanfordpath
https://pbs.twimg.com/profile_images/747923625727033344/mI29fR9m_normal.jpg
RT @YasmeenButtMD: Assessing tumor cellularity. @Sinchita_Roy #CBCII #pathologists https://t.co/6mTKQQeGew
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
#Cytology specimens are tumor enriched&not formalin fixed, can lower minimum amt of DNA needed @Sinchita_Roy #CBCII https://t.co/WVS5QYbgIj
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
Cytology is underutilized! @Sinchita_Roy #CBCII #pathologists #cytopath https://t.co/Tk9hDjPs86
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
RT @marenwhymd: #Cytology specimens are tumor enriched&not formalin fixed, can lower minimum amt of DNA needed @Sinchita_Roy #CBCII https://t.co/WVS5QYbgIj
carnold_gi
https://pbs.twimg.com/profile_images/664520482520076288/8lW_MVDD_normal.jpg
RT @euthman: Which GE junction adenoca pts benefit from her2 testing? #CBCII https://t.co/BATkFEnM4n
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
#Cytology has great potential for #moldx, but validation remains a problem -@Sinchita_Roy #CBCII https://t.co/AdrZUeOfyY
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @Pathology20: Advantages and Disadvantages of Molecular Testing of Cytology Specimens #CBCII @Pathologists https://t.co/2KDGnUZomG
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
Next up at #CBCII , Dara L. Aisner on regulation and billing of molecular testing.
chrisventura04
https://pbs.twimg.com/profile_images/579477282575626240/A66eg1mi_normal.jpg
RT @Robyn_Temple: Hope you have a great #CBCII @PhilipTCagle!
onicapinzon
https://pbs.twimg.com/profile_images/722448201060515841/3QooEN1q_normal.jpg
RT @tissuepathology: Dr. Dan Hayes, ASCO President on Circulating "Liquid" vs. Tissue Biopsy #CBCII https://t.co/RRvuHxdChB
rickgomezmd
https://pbs.twimg.com/profile_images/378800000595275104/afcb95e35ca830896f87e02979a79bfa_normal.jpeg
RT @TimAllenMDJD: #CBCII is underway! #StandingRoomOnly https://t.co/hciMgLF5US
chrisventura04
https://pbs.twimg.com/profile_images/579477282575626240/A66eg1mi_normal.jpg
RT @TimAllenMDJD: #CBCII is underway! #StandingRoomOnly https://t.co/hciMgLF5US
drsybenga
https://pbs.twimg.com/profile_images/595981337196163072/OxROyC10_normal.jpg
RT @euthman: "Constantly choosing the lesser of two evils is still evil."—Jerry Garcia. #CBCII https://t.co/qIpfHo5qUw
carnold_gi
https://pbs.twimg.com/profile_images/664520482520076288/8lW_MVDD_normal.jpg
RT @TimAllenMDJD: #CBCII is underway! #StandingRoomOnly https://t.co/hciMgLF5US
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Dr Dana Aisner on Regulation and Billing for #moldx 🔬💸 #CBCII https://t.co/OWiwOZpqJo
deepathdx
https://pbs.twimg.com/profile_images/782631311877877760/FjMp4mBD_normal.jpg
RT @TimAllenMDJD: #CBCII is underway! #StandingRoomOnly https://t.co/hciMgLF5US
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Relevant for #CBCII @Sinchita_Roy https://t.co/QhswhigkGg
drsybenga
https://pbs.twimg.com/profile_images/595981337196163072/OxROyC10_normal.jpg
RT @YasmeenButtMD: Cytology is underutilized! @Sinchita_Roy #CBCII #pathologists #cytopath https://t.co/Tk9hDjPs86
bhas_dr
https://pbs.twimg.com/profile_images/778226429724987396/XxeHRyJD_normal.jpg
RT @marenwhymd: #Cytology specimens are tumor enriched&not formalin fixed, can lower minimum amt of DNA needed @Sinchita_Roy #CBCII https://t.co/WVS5QYbgIj
alboothmd
https://pbs.twimg.com/profile_images/679792086942494720/1mP1gABa_normal.jpg
Excited to be at #CBCII @TimAllenMDJD @PhilipTCagle @DrSybenga @YasmeenButtMD @marenwhymd https://t.co/8lPTyY8MeO
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
What is a lab-developed test (LDT)? #CBCII https://t.co/zYDYI9AyID
pathology20
https://pbs.twimg.com/profile_images/561663935980793856/0fM_co_B_normal.jpeg
RT @marenwhymd: Again, the Her2 #breastcancer story as a paradigm for biomarkers: Preanalytic variables matter! #CBCII @Sinchita_Roy https://t.co/1uxF3F4aOl
smlungpathguy
https://pbs.twimg.com/profile_images/780941743004880896/M03kC6kx_normal.jpg
RT @TimAllenMDJD: #CBCII is underway! #StandingRoomOnly https://t.co/hciMgLF5US
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
FDA on LDTs: same as required for medical device like pacemaker➡️"square hole round peg problem" -Dr Aisner #CBCII https://t.co/j3mjrn1jKW
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @ALBoothMD: Excited to be at #CBCII @TimAllenMDJD @PhilipTCagle @DrSybenga @YasmeenButtMD @marenwhymd https://t.co/8lPTyY8MeO
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @euthman: What is a lab-developed test (LDT)? #CBCII https://t.co/zYDYI9AyID
deepathdx
https://pbs.twimg.com/profile_images/782631311877877760/FjMp4mBD_normal.jpg
Class I-III risk-based submissions for oncology LDTs: PMA (Class III) or 510k (Class II) #CBCII
alboothmd
https://pbs.twimg.com/profile_images/679792086942494720/1mP1gABa_normal.jpg
RT @YasmeenButtMD: Cytology is underutilized! @Sinchita_Roy #CBCII #pathologists #cytopath https://t.co/Tk9hDjPs86
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
Overview of LDT oversight proposals. #CBCII #pathologists https://t.co/NREqvWjRfM
mariglesiascoma
https://pbs.twimg.com/profile_images/714504646824431618/eVaNP1AO_normal.jpg
RT @euthman: Which GE junction adenoca pts benefit from her2 testing? #CBCII https://t.co/BATkFEnM4n
bhas_dr
https://pbs.twimg.com/profile_images/778226429724987396/XxeHRyJD_normal.jpg
RT @Pathology20: Advantages and Disadvantages of Molecular Testing of Cytology Specimens #CBCII @Pathologists https://t.co/2KDGnUZomG
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @YasmeenButtMD: Overview of LDT oversight proposals. #CBCII #pathologists https://t.co/NREqvWjRfM
bhas_dr
https://pbs.twimg.com/profile_images/778226429724987396/XxeHRyJD_normal.jpg
RT @marenwhymd: #Cytology has great potential for #moldx, but validation remains a problem -@Sinchita_Roy #CBCII https://t.co/AdrZUeOfyY
drsybenga
https://pbs.twimg.com/profile_images/595981337196163072/OxROyC10_normal.jpg
What we should be planning @Pathologists @TimAllenMDJD #CBCII NOT @US_FDA duplication of regulations https://t.co/0kiY9SOT6N
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
@UTMBPath well represented! #CBCII https://t.co/EsVix4wkOg
drsybenga
https://pbs.twimg.com/profile_images/595981337196163072/OxROyC10_normal.jpg
RT @ALBoothMD: Excited to be at #CBCII @TimAllenMDJD @PhilipTCagle @DrSybenga @YasmeenButtMD @marenwhymd https://t.co/8lPTyY8MeO
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
RT @DrSybenga: What we should be planning @Pathologists @TimAllenMDJD #CBCII NOT @US_FDA duplication of regulations https://t.co/0kiY9SOT6N
euthman
https://pbs.twimg.com/profile_images/719139234355896320/I4obXeHv_normal.jpg
USFDA regulates NGS testing as a high-risk medical device. #CBCII
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @DrSybenga: What we should be planning @Pathologists @TimAllenMDJD #CBCII NOT @US_FDA duplication of regulations https://t.co/0kiY9SOT6N
elinsilveous
https://pbs.twimg.com/profile_images/463466580052295681/GLoU2EA4_normal.jpeg
RT @healthhashtags: Today's Healthcare Conferences: #wais #dgfn2016 #wais2016 #CIRSE2016 #CBCII https://t.co/YnZewsLKhm #hcsm
cbslabs
https://pbs.twimg.com/profile_images/614495543478190080/A8QuFLwr_normal.png
RT @marenwhymd: #Cytology specimens are tumor enriched&not formalin fixed, can lower minimum amt of DNA needed @Sinchita_Roy #CBCII https://t.co/WVS5QYbgIj
cbslabs
https://pbs.twimg.com/profile_images/614495543478190080/A8QuFLwr_normal.png
RT @marenwhymd: #Cytology has great potential for #moldx, but validation remains a problem -@Sinchita_Roy #CBCII https://t.co/AdrZUeOfyY
adamgomezmd
https://pbs.twimg.com/profile_images/825762402377539584/c0S2Nmd2_normal.jpg
@marenwhymd @Sinchita_Roy I looked it up after seeing your and @YasmeenButtMD's tweets from #CBCII
cbslabs
https://pbs.twimg.com/profile_images/614495543478190080/A8QuFLwr_normal.png
RT @marenwhymd: Dr Dana Aisner on Regulation and Billing for #moldx 🔬💸 #CBCII https://t.co/OWiwOZpqJo
cbslabs
https://pbs.twimg.com/profile_images/614495543478190080/A8QuFLwr_normal.png
RT @marenwhymd: FDA on LDTs: same as required for medical device like pacemaker➡️"square hole round peg problem" -Dr Aisner #CBCII https://t.co/j3mjrn1jKW
bhas_dr
https://pbs.twimg.com/profile_images/778226429724987396/XxeHRyJD_normal.jpg
RT @marenwhymd: Molecular testing on #cytology specimens. #cytologyrules, but don't forget validation! @Sinchita_Roy #CBCII https://t.co/DVTKnPdkdz
cbslabs
https://pbs.twimg.com/profile_images/614495543478190080/A8QuFLwr_normal.png
RT @euthman: What is a lab-developed test (LDT)? #CBCII https://t.co/zYDYI9AyID
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: Again, the Her2 #breastcancer story as a paradigm for biomarkers: Preanalytic variables matter! #CBCII @Sinchita_Roy https://t.co/1uxF3F4aOl
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: Potential sources of preanalytical test variability. #CBCII https://t.co/QdU0C8zgi9
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: Summary of recs for preanalytic handling for FFPE #CBCII @Sinchita_Roy https://t.co/5nl9QMKwOB
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: Molecular testing on #cytology specimens. #cytologyrules, but don't forget validation! @Sinchita_Roy #CBCII https://t.co/DVTKnPdkdz
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
RT @Pathology20: Advantages and Disadvantages of Molecular Testing of Cytology Specimens #CBCII @Pathologists https://t.co/2KDGnUZomG
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: #Cytology specimens are tumor enriched&not formalin fixed, can lower minimum amt of DNA needed @Sinchita_Roy #CBCII https://t.co/WVS5QYbgIj
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: #Cytology has great potential for #moldx, but validation remains a problem -@Sinchita_Roy #CBCII https://t.co/AdrZUeOfyY
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
Complete gamechanger➡️FDA explores potential use of curated cancer databases -Dr Aisner #CBCII https://t.co/zmwOKmYcJG
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @Pathology20: Advantages and Disadvantages of Molecular Testing of Cytology Specimens #CBCII @Pathologists https://t.co/2KDGnUZomG
teresalimjocomd
https://pbs.twimg.com/profile_images/676970235627503616/pGKwS5VB_normal.jpg
RT @evemariecrane: First US olympic gold medalist in figure skating-1956, also studied #biomarkers wow #STEMWomen Inspiring for #CBCII! https://t.co/wcanHtl4ef
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: Dr Dana Aisner on Regulation and Billing for #moldx 🔬💸 #CBCII https://t.co/OWiwOZpqJo
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @marenwhymd: FDA on LDTs: same as required for medical device like pacemaker➡️"square hole round peg problem" -Dr Aisner #CBCII https://t.co/j3mjrn1jKW
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: What is a lab-developed test (LDT)? #CBCII https://t.co/zYDYI9AyID
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @YasmeenButtMD: Overview of LDT oversight proposals. #CBCII #pathologists https://t.co/NREqvWjRfM
timallenmdjd
https://pbs.twimg.com/profile_images/769180595201060864/3Be7NWgh_normal.jpg
RT @YasmeenButtMD: Cytology is underutilized! @Sinchita_Roy #CBCII #pathologists #cytopath https://t.co/Tk9hDjPs86
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
RT @AdamGomezMD: @marenwhymd @Sinchita_Roy I looked it up after seeing your and @YasmeenButtMD's tweets from #CBCII
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @DrSybenga: What we should be planning @Pathologists @TimAllenMDJD #CBCII NOT @US_FDA duplication of regulations https://t.co/0kiY9SOT6N
mvmd0908
https://pbs.twimg.com/profile_images/3701221689/4fecd7c62afe6ce7715060e9d6f876a1_normal.jpeg
RT @euthman: USFDA regulates NGS testing as a high-risk medical device. #CBCII
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
The other depressing topic... #CBCII #pathologists https://t.co/xVVC0Q1hGG
drsybenga
https://pbs.twimg.com/profile_images/595981337196163072/OxROyC10_normal.jpg
" @Pathologists has been ahead of the [regulatory] game" compared to @US_FDA ~Dara Aisner #CBCII
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @YasmeenButtMD: The other depressing topic... #CBCII #pathologists https://t.co/xVVC0Q1hGG
sara_jiang
https://pbs.twimg.com/profile_images/743117496023195648/Wj_hDxYt_normal.jpg
RT @YasmeenButtMD: Promise of personalized therapy in lung cancer. #CBCII #pathologists #pulmpath https://t.co/TpLyZzm8PH
ahmed82albakosh
https://pbs.twimg.com/profile_images/764182497995264000/MuJpgqoX_normal.jpg
RT @tissuepathology: Dr. Dan Hayes, ASCO Pres, kicks off Cancer Biomarkers "Perspectives on the Future of Cancer Biomarkers". #CBCII https://t.co/GK9iiQ2bPq
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @DrSybenga: " @Pathologists has been ahead of the [regulatory] game" compared to @US_FDA ~Dara Aisner #CBCII
drjimbonhs
https://pbs.twimg.com/profile_images/727069263626915840/b41PLqpl_normal.jpg
RT @marenwhymd: Complete gamechanger➡️FDA explores potential use of curated cancer databases -Dr Aisner #CBCII https://t.co/zmwOKmYcJG
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
CPT tier 1 & 2. #CBCII #pathologists https://t.co/k1JSGHf3Jt
alboothmd
https://pbs.twimg.com/profile_images/679792086942494720/1mP1gABa_normal.jpg
RT @DrSybenga: What we should be planning @Pathologists @TimAllenMDJD #CBCII NOT @US_FDA duplication of regulations https://t.co/0kiY9SOT6N
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
RT @YasmeenButtMD: CPT tier 1 & 2. #CBCII #pathologists https://t.co/k1JSGHf3Jt
sara_jiang
https://pbs.twimg.com/profile_images/743117496023195648/Wj_hDxYt_normal.jpg
RT @marenwhymd: #Cytology specimens are tumor enriched&not formalin fixed, can lower minimum amt of DNA needed @Sinchita_Roy #CBCII https://t.co/WVS5QYbgIj
sara_jiang
https://pbs.twimg.com/profile_images/743117496023195648/Wj_hDxYt_normal.jpg
RT @tissuepathology: Advantages and Disadvantages of Molecular Testing of Cytology Specimens #CBCII @Pathologists https://t.co/dpzBfMC4Kc
sara_jiang
https://pbs.twimg.com/profile_images/743117496023195648/Wj_hDxYt_normal.jpg
RT @marenwhymd: Molecular testing on #cytology specimens. #cytologyrules, but don't forget validation! @Sinchita_Roy #CBCII https://t.co/DVTKnPdkdz
yasmeenbuttmd
https://pbs.twimg.com/profile_images/650791925457534976/r2nQ7aSh_normal.jpg
Jumping through hoops for payment. #CBCII #pathologists https://t.co/3lUajQXdhQ
robyn_temple
https://pbs.twimg.com/profile_images/631506130892640256/VgHCIwHF_normal.jpg
RT @DrSybenga: What we should be planning @Pathologists @TimAllenMDJD #CBCII NOT @US_FDA duplication of regulations https://t.co/0kiY9SOT6N
marenwhymd
https://pbs.twimg.com/profile_images/732947736832540675/kBNrlMgV_normal.jpg
PAMA in a nutshell: 💸💸💸 #CBCII https://t.co/yj2Qupsecc